The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Business services providers thrive by solving complex operational challenges for their clients, allowing them to focus on ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH ...

A new Equifax® (NYSE:EFX) survey shows that human resources (HR) leaders are facing challenges using technology innovation to ...

Generation IM’s Q2 2025 portfolio value declined to $15.73B, with 37 positions. Click here to read more about the portfolio's ...

Individual brings two decades of industry experience to his new role, and has also previously worked at Refinitiv, Bloomberg ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

Will Douglas has joined IMC Trading as a FX options trader. London-based Douglas brings previous experience in automated ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...